or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein

A is taken from the group consisting of –N(R2)R3 and G;

G is selected from the group consisting of



and wherein the symbol (**) is the point of attachment to the pyrimidine ring;

each G moiety may be further substituted with one, two, or three R4 moieties;

W is C5-C6heteroaryl, phenyl, -NHC(O)R6, -NHC(O)R7, -NHC(O)N(R8)R9 or -C(O)N(R8)R9, and wherein each C5-C6heteroaryl or phenyl is optionally substituted by one, two, or three R5 moieties;

X1 and X2 are individually and independently hydrogen or C1-C6 alkyl;

R1 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl;

R2 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m$-OR8, or a 3-8 membered non-aromatic heterocycle, wherein each alkylene is optionally substituted with C1-C4 alkyl;

R3 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered non-aromatic heterocycle;

each R4 is individually and independently hydrogen, halogen, C1-C6 alkyl, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, branched C3-C8 alkyl, C3-C8 cycloalkyl, $-(CH_2)_m$-OR8, $-(CH_2)_m$-NR8(R9), $-(CH_2)_m$-R7, or cyano, wherein each alkylene is optionally substituted with C1-C4 alkyl;

each R5 is individually and independently hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, halogen, cyano, fluoro-C1-C6 alkyl wherein the alkyl chain is partially or completely fluorinated, $-(CH_2)_m$-C(O)NR8(R9), $-(CH_2)_m$-C(O)R7, $-(CH_2)_m$-OR8, $-(CH_2)_m$-NR8(R9), or $-(CH_2)_m$-R7, wherein each alkylene is optionally substituted with C1-C4 alkyl;

CLAIMS

What is claimed is:

1. A compound of **Formula I**,



Formula I

or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, wherein

A is taken from the group consisting of –N(R2)R3 and G;

G is selected from the group consisting of



and wherein the symbol (**) is the point of attachment to the pyrimidine ring;

each G moiety may be further substituted with one, two, or three R4 moieties;

W is C5-C6heteroaryl, phenyl, -NHC(O)R6, -NHC(O)R7, -NHC(O)N(R8)R9 or -C(O)N(R8)R9, and wherein each C5-C6heteroaryl or phenyl is optionally substituted by one, two, or three R5 moieties;

X1 and X2 are individually and independently hydrogen or C1-C6 alkyl;

R1 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, or branched C3-C8 alkyl;

R2 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated, $-(CH_2)_m$-OR8, or a 3-8 membered non-aromatic heterocycle, wherein each alkylene is optionally substituted with C1-C4 alkyl;

R3 is hydrogen, C1-C6 alkyl, deutero-C1-C6 alkyl wherein the alkyl chain is partially or completely deuterated, branched C3-C8 alkyl, C3-C8 cycloalkyl, fluoroC1-C6alkyl wherein the alkyl is fully or partially fluorinated or a 3-8 membered non-aromatic heterocycle;